In this podcast from the Thoracic Oncology Group of Australasia (TOGA), Professor Anna Nowak, Pro Vice Chancellor at UWA, Medical Oncologist and Director of the National Centre for Asbestos Related Diseases talks with Medical Oncologist Dr Steven Kao from the Chris O’Brien Lifehouse and the Asbestos Diseases Research Institute (ADRI) in Sydney. They discuss the recent CONFIRM Trial led by Dean Fennell in the UK, emerging treatments for mesothelioma patients, the DREAM trial and the newly opened Phase III trial DREAM3R.
DREAM3R is the result of a successful partnership spanning US, Australia and New Zealand. TOGA investigators are collaborating with the Philadelphia based clinical trials group PrECOG and the NHMRC Clinical Trials Centre (CTC) in Sydney. DREAM3R (pronounced dreamer) is investigating the addition of immunotherapy to chemotherapy in patients with newly diagnosed malignant pleural mesothelioma. The DREAM3R trial follows on from the exciting Phase II clinical trial results in PrECOG’s PrE0505 trial and the Australian DREAM trial that both showed early promising results with the chemotherapy and durvalumab combination. More information on the DREAM3R trial can be found at Cancer Australia and the Australian New Zealand Clinical Trials Registry